BIRC3 Antibodies

Baculoviral IAP repeat-containing protein 3 (BIRC3)

Multi-functional protein which modulates not just caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin- protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling.

The target proteins for its E3 ubiquitin- protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), jointly called pattern recognition receptors (PRRs).

Gene Information

Human
Gene Name:	BIRC3
Uniprot:	Q13489
Entrez:	330

Family

Belongs to:
IAP family

Alternative Names

AIP1; API2; BIRC3 baculoviral IAP repeat containing 3; BIRC3; cIAP2; c-IAP2; cIAP-2; HAIP1; HIAP1; HIAP-1; MALT2; MIHC; RNF49

Molecular Weight

Mass (kDA):
68.372 kDA

Genomic Context

Human
Location:	11q22.2
Sequence:	11; NC_000011.10 (102317373..102339403)

Tissue Specificity

Highly expressed in fetal lung, and kidney. In the adult, expression is mainly seen in lymphoid tissues, including spleen, thymus and peripheral blood lymphocytes.

Subcellular Localizations

Cytoplasm. Nucleus.

Diseases

• Malignant Neoplasms
• Neoplasms
• Inflammation
• Carcinoma
• Malignant Neoplasm Of Breast
• Leukemia
• Malignant Paraganglionic Neoplasm
• Lymphoma
• Mammary Neoplasms
• Cell Transformation, Neoplastic
• B-cell Lymphomas
• Multiple Myeloma
• Prostatic Neoplasms

• Carcinogenesis
• Malignant Squamous Cell Neoplasm
• Neoplasm Metastasis
• Hypoxia
• Malignant Neoplasm Of Prostate
• Tissue Adhesions
• Lymphoid Leukemia

Interacting Proteins

• CASP9
• RIPK1
• RIPK2
• RIPK3
• RIPK4

• TRAF1
• TRAF2
• UBE2D2
• UBE2N

Pathways

• Cell Death
• Cell Growth
• Cell Proliferation
• Pathogenesis
• Cell Cycle
• Programmed Cell Death
• Rna Interference
• Oncogenesis
• Induction Of Apoptosis
• Sensitization
• Reverse Transcription
• Angiogenesis
• Transport

• Cell Cycle Arrest
• Inflammatory Response
• Translation
• Localization
• Cell Differentiation
• Dna Methylation
• Regeneration

PTMs

• Phosphorylation
• Cleavage

• Ubiquitination
• Acetylation

• Methylation

Research Areas

• Apoptosis
• Inhibitors, Activators and Regulators

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/BIRC3

Best Uses Of The BIRC3 Marker

This article will cover the BIRC3 marker and Steven Boster's genetic infographics. If you've never been aware of the BIRC3 Marker Let's go over what it is and how you can use it to your research. Boster's Gene Infographics make use of the BIRC3Marker to display how many genes are present in the genome of a person.

BIRC3 Marker

BIRC3 is an IAP gene. IAP family. It is the most well-known of the eight human IAP genes and is expressed by tissues that are developing. Adult cells don't express the protein, however it is frequently expressed in cancerous tumors. Survivin expression is linked with its expression, and has been demonstrated to be present in various types types of cancer. This gene has the potential to be a candidate for druggable targets in the area of cancer research.

The BIRC3 gene is expressed on the 11q22.2 band of the human genome. Its expression in CLL has been proven to be higher than normal lymphocytes. It is located on the same DNA chromosome as ATM. CLL patients who have BIRC3 removed are more likely to suffer an unfavorable prognosis than those who have other types of cancer. They also have a shorter PFS and OS.

BIRC3 expression is differentially expressed in 32 types of cancer. It has been proven to be associated with metastasis. BIRC3 could be a potential therapeutic target for cancerous gliomas. Researchers also have reported that this marker is associated with a shorter PFS and OS as compared to BIRC2-positive cancer patients. Research also shows that BIRC3 is a major contributor to the growth of tumors.

The BIRC3 gene is a member of the IAP family. This gene is utilized by most cancer cells to fight Apoptosis. GBM patients with BIRC3 expression are more likely to live for five years. Expression was also linked to the development of chemotherapy resistance and radiotherapy. It is a fascinating marker to study cancer research. It is being studied extensively in a number of clinical trials.

SMAC mimetics are able to target the BIRC3 gene as an option for treatment. It is found in approximately 3 percent of CLL cases and is associated with poor prognosis. There is evidence that BIRC3 plays a pro-survival role against cancer cells. Additionally, genetic inactivation of BIRC3 is associated with shorter cancer-free survival and chemoimmunotherapy resistance. BIRC3 expression is linked to progress from low-grade gliomas into more advanced gliomas. The connection between BIRC3 and prognosis has been significant.

BIRC3 is a candidate for numerous applications. It blocks the B-cell receptor signal path that is involved in the development and pathogenesis of MCL. In addition to its prognostic function, BIRC3 is also an important molecular marker to detect short-distance transport stress. Further, it is a useful tool in gene therapy.

BIRC3 Marker in Boster Bio

BIRC3 is part of the family of inhibitors of apoptosis. It directly reduces the activity of caspase 3 and blocks apoptosis. The overexpression of BIRC3 has been associated with chemo-resistance in a variety of types of cancer, including ovarian and lung cancers. Additionally, 5-Fu chemotherapy was associated with a shorter survival rate. Moreover, it has been associated with an increase in cell movement and metastasis in Hepatocellular carcinoma.

The loss of regulation of BIRC3 in cancer cells isn't foreseeable. Its mechanism could be transcriptional, genetic or the combination of both. There is a variety of contradicting research evidence that supports a multi-faceted function of BIRC3 however, current research on the potential for tumor-promoting abilities of BIRC3 has led to a broad range of anti-tumor activities. For these reasons, it has become a significant treatment option in biotherapeutics.